The Central Drugs Standard Control Organisation (CDSCO) has issued a letter to all pharma industry associations expressing the low inventory level of cardiac and anti-diabetic medicines at the distributor level.

The CDSCO letter to all pharma associations states that it has received a communication from the National Pharmaceutical Pricing Authority (NPPA), letter  no 37001/2020/ Div III/ NPPA dated April 24, 2020 wherein they have noted that cardiac and anti-diabetic drugs including insulin stocks level are below than normal.

Commenting on the market availability of these medicines in the market, Rajiv Singhal, General Secretary, All India Organisation of Chemists and Druggist (AIOCD) said, "We have recently checked the market stock availability of all the medicines through our C&F agent and realised that there is no shortages of any medicines as on date, also there are sufficient stock available with the companies to feed the market requirements."

Anil Khanna, Partner, Wisdomsmith Advisors LLP explained, "In the month of February, the inventory for both these therapies was nearly 40 days. And this inventory was at the stockists level. Add to it, nearly 7-10 days would be at the retail level, further add on inventory would be at the plant. So total inventory could be around 75 days. Hence, I don’t feel that there would be shortage/ low level of inventory at the distributor level."

However, Sudarshan Jain, Secretary General,  Indian Pharmaceutical Alliance (IPA) justifies the move and said, " This could be the market assessment exercise by the government to ensure that there is no shortage of medicines at any given point of time. As of now there is no shortage or low level of inventory of these medicines, including insulins in the market, however if the production is not resumed completely then there are possibilities of facing such problems."

Dr Shashank Joshi, Chairman International Diabetes Federation, South East Asia said, "At present, we have not come across with any information about the shortage of diabetes medicines or insulins. In fact, if at all, any patient is finding difficulties in sourcing them, we are ensuring from our team that get access to the medicines during the pandemic due to COVID-19."

The letter to all the associations from the CDSCO has also requested to take urgent, necessary action to ensure sufficient availability of anti-diabetic and cardiac medicines at all times. It also requested to issue instructions to the drug manufacturing companies to accelerate their operations and ensure the replenishment of stocks of medicines through wholesalers/distributors/retailer/ chemists so as to reach the hospital/ clinics and to patients as well.

In continuation to this, the NPPA has also requested the CDSCO to provide the details of manufacture of cardiac and anti-diabetic drugs, especially in respect of insulin, aspirin and atorvastatin like name of manufacture/ importers and contact details, manufacturing capacity, production of February, March and April 2020, average monthly import quantity, monthly import quantity of  February, March and April 2020 and stock position as of March 31 and April 15, 2020.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.